作動薬　　　

WordNet

(biochemistry) a drug that can combine with a receptor on a cell to produce a physiological reaction
a muscle that contracts while another relaxes; "when bending the elbow the biceps are the agonist"
someone involved in a contest or battle (as in an agon)
a substance that exerts some force or effect
a businessman who buys or sells for another in exchange for a commission (同)factor, broker
any agent or representative of a federal agency or bureau (同)federal agent
a representative who acts on behalf of other persons or organizations
an active and efficient cause; capable of producing a certain effect; "their research uncovered new disease agents"
of or relating to the athletic contests held in ancient Greece
striving to overcome in argument; "a dialectical and agonistic approach" (同)agonistical, combative
struggling for effect; "agonistic poses" (同)strained
that stimulates; "stimulant phenomena" (同)stimulating
a drug that temporarily quickens some vital process (同)stimulant_drug, excitant

PrepTutorEJDIC

『代理人』;周旋人 / 働き(作用)を起こすもの;作用物,薬剤 / (政府機関,特にFBI,CIAなどの)部員,機関員
刺激[するもの] / 興奮性飲食物

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2014/11/19 13:23:27」(JST)

wiki en

[Wiki en表示]

Agonists activating hypothetical receptors.

Efficacy spectrum of receptor ligands.

An agonist is a chemical that binds to a receptor and activates the receptor to produce a biological response. Whereas an agonist causes an action, an antagonist blocks the action of the agonist and an inverse agonist causes an action opposite to that of the agonist.

Types of agonists

Receptors can be activated by either endogenous (such as hormones and neurotransmitters) or exogenous (such as drugs) agonists, resulting in a biological response. A physiological agonist is a substance that creates the same bodily responses but does not bind to the same receptor.

An endogenous agonist for a particular receptor is a compound naturally produced by the body that binds to and activates that receptor. For example, the endogenous agonist for serotonin receptors is serotonin, and the endogenous agonist for dopamine receptors is dopamine.^[1]

A superagonist is a compound that is capable of producing a greater maximal response than the endogenous agonist for the target receptor, and thus has an efficacy of more than 100%. This does not necessarily mean that it is more potent than the endogenous agonist, but is rather a comparison of the maximum possible response that can be produced inside the cell following receptor binding.

Full agonists bind (have affinity for) and activate a receptor, producing full efficacy at that receptor. One example of a drug that acts as a full agonist is isoproterenol, which mimics the action of adrenaline at β adrenoreceptors. Another example is morphine, which mimics the actions of endorphins at μ-opioid receptors throughout the central nervous system.

Partial agonists (such as buspirone, aripiprazole, buprenorphine, or norclozapine) also bind and activate a given receptor, but have only partial efficacy at the receptor relative to a full agonist, even at maximal receptor occupancy. Agents like buprenorphine are used to treat opiate dependence for this reason, as they produce milder effects on the opioid receptor with lower dependence and abuse potential.

An inverse agonist is an agent that binds to the same receptor binding-site as an agonist for that receptor and inhibits the constitutive activity of the receptor. Inverse agonists exert the opposite pharmacological effect of a receptor agonist, not merely an absence of the agonist effect as seen with antagonist. An example is the cannabinoid inverse agonist rimonabant.

A co-agonist works with other co-agonists to produce the desired effect together. NMDA receptor activation requires the binding of both glutamate, glycine and D-serine co-agonists.

An irreversible agonist is a type of agonist that binds permanently to a receptor through the formation of covalent bonds. A few of these have been described.^[2]^[3]

A selective agonist is selective for a specific type of receptor. E.g. buspirone is a selective agonist for serotonin 5-HT1A.

New findings that broaden the conventional definition of pharmacology demonstrate that ligands can concurrently behave as agonist and antagonists at the same receptor, depending on effector pathways or tissue type. Terms that describe this phenomenon are "functional selectivity", "protean agonism",^[4]^[5] or selective receptor modulators.^[6]

Activity

Potency

The potency of an agonist is inversely related to its EC₅₀ value. The EC₅₀ can be measured for a given agonist by determining the concentration of agonist needed to elicit half of the maximum biological response of the agonist. The EC₅₀ value is useful for comparing the potency of drugs with similar efficacies producing physiologically similar effects. The smaller the EC₅₀ value, the greater the potency of the agonist, the lower the concentration of drug that is required to elicit the maximum biological response.

Therapeutic index

When a drug is used therapeutically, it is important to understand the margin of safety that exists between the dose needed for the desired effect and the dose that produces unwanted and possibly dangerous side-effects (measured by the TD₅₀, the dose that produces toxicity in 50% of individuals). This relationship, termed the therapeutic index, is defined as the ratio TD₅₀:ED₅₀. In general, the narrower this margin, the more likely it is that the drug will produce unwanted effects. The therapeutic index emphasizes the importance of the margin of safety, as distinct from the potency, in determining the usefulness of a drug.

Etymology

From the Greek αγωνιστής (agōnistēs), contestant; champion; rival < αγων (agōn), contest, combat; exertion, struggle < αγω (agō), I lead, lead towards, conduct; drive

References

^ Goodman and Gilman's Manual of Pharmacology and Therapeutics. (11th edition, 2008). p14. ISBN 0-07-144343-6
^ De Mey JGR, Compeer MG, Meens MJ (2009). "Endothelin-1, an Endogenous Irreversible Agonist in Search of an Allosteric Inhibitor". Mol Cell Pharmacol 1 (5): 246–257.
^ Rosenbaum DM, Zhang C, Lyons JA, Holl R, Aragao D, Arlow DH, Rasmussen SG, Choi HJ, Devree BT, Sunahara RK, Chae PS, Gellman SH, Dror RO, Shaw DE, Weis WI, Caffrey M, Gmeiner P, Kobilka BK (January 2013). "Structure and function of an irreversible agonist-β(2) adrenoceptor complex". Nature 469 (7329): 236–40. doi:10.1038/nature09665. PMC 3074335. PMID 21228876.
^ Kenakin T (March 2001). "Inverse, protean, and ligand-selective agonism: matters of receptor conformation". FASEB J. 15 (3): 598–611. doi:10.1096/fj.00-0438rev. PMID 11259378.
^ Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka B, Weinstein H, et al. (January 2007). "Functional selectivity and classical concepts of quantitative pharmacology". J. Pharmacol. Exp. Ther. 320 (1): 1–13. doi:10.1124/jpet.106.104463. PMID 16803859.
^ Smith CL, O'Malley BW (February 2004). "Coregulator function: a key to understanding tissue specificity of selective receptor modulators". Endocr. Rev. 25 (1): 45–71. doi:10.1210/er.2003-0023. PMID 14769827.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. パーキンソン病の薬理学的治療 pharmacologic treatment of parkinson disease
2. 癌免疫療法の原則 principles of cancer immunotherapy
3. Sleep-wake disturbances and sleep disorders in patients with dementia
4. 思春期における多嚢胞性卵巣症候群の診断的評価 diagnostic evaluation of polycystic ovary syndrome in adolescents
5. 小児における、アデノイド切除同時施行例を含む扁桃摘出に対する麻酔 anesthesia for tonsillectomy with or without adenoidectomy in children

English Journal

Differentiation of PC12 cells expressing estrogen receptor alpha: A new bioassay for endocrine-disrupting chemicals evaluation.

Habauzit D1, Ferrière F2, Botherel N2, Flouriot G2, Pakdel F3, Saligaut C2.
Chemosphere.Chemosphere.2014 Oct;112C:240-247. doi: 10.1016/j.chemosphere.2014.03.101. Epub 2014 May 14.
Xeno-estrogens, a class of endocrine disrupting chemicals (EDCs), can disturb estrogen receptor-dependent pathways involved in differentiation, proliferation or protection. Multiple methods have been developed to characterize the disturbances induced by EDCs in different cells or organs. In this stu
PMID 25048912

The selective PAC1 receptor agonist maxadilan inhibits neurogenic vasodilation and edema formation in the mouse skin.

Banki E1, Hajna Z2, Kemeny A2, Botz B2, Nagy P2, Bolcskei K2, Toth G3, Reglodi D1, Helyes Z4.
Neuropharmacology.Neuropharmacology.2014 Oct;85:538-47. doi: 10.1016/j.neuropharm.2014.06.019. Epub 2014 Jun 25.
We have earlier shown that PACAP-38 decreases neurogenic inflammation. However, there were no data on its receptorial mechanism and the involvement of its PAC1 and VPAC1/2 receptors (PAC1R, VPAC1/2R) in this inhibitory effect. Neurogenic inflammation in the mouse ear was induced by topical applicati
PMID 24973707

Negative allosteric modulation of mGlu5 receptor rescues striatal D2 dopamine receptor dysfunction in rodent models of DYT1 dystonia.

Sciamanna G1, Ponterio G1, Tassone A2, Maltese M3, Madeo G3, Martella G1, Poli S4, Schirinzi T3, Bonsi P2, Pisani A5.
Neuropharmacology.Neuropharmacology.2014 Oct;85:440-50. doi: 10.1016/j.neuropharm.2014.06.013. Epub 2014 Jun 19.
Early onset torsion dystonia (DYT1) is an autosomal dominantly inherited disorder caused by deletion in TOR1A gene. Evidence suggests that TOR1A mutation produces dystonia through an aberrant neuronal signalling within the striatum, where D2 dopamine receptors (D2R) produce an abnormal excitatory re
PMID 24951854

Two rare variations, D478N and D478E, that occur at the same amino acid residue in nicotinic acetylcholine receptor (nAChR) α2 subunit influence nAChR function.

Dash B1, Li MD2.
Neuropharmacology.Neuropharmacology.2014 Oct;85:471-81. doi: 10.1016/j.neuropharm.2014.05.014. Epub 2014 Jun 17.
There occur two rare variations, Asp(D)478Asn(N) and Asp(D)478Glu(E), in the putative cytoplasmic amphipathic α-helices of human nicotinic acetylcholine receptor (nAChR) α2 subunit as a result of mutation in the 1st (G → A: rs141072985) and 3rd (C → A: rs56344740) nucleotide of its 478th t
PMID 24950454

Japanese Journal

LH-RHアゴニストとLH-RHアンタゴニスト (特集前立腺癌の内分泌療法 : 気になる最新の動向)

計屋知彰,酒井英樹
臨床泌尿器科 = Japanese journal of clinical urology 69(5), 334-338, 2015-04
NAID 40020400394

Decreased expression of human heat shock protein 70 in the endometria and pathological lesions of women with adenomyosis and uterine myoma after GnRH agonist therapy

Khan Khaleque Newaz,Kitajima Michio,Hiraki Koichi,Fujishita Akira,Nakashima Masahiro,Masuzaki Hideaki
European Journal of Obstetrics & Gynecology and Reproductive Biology 187, 6-13, 2015-04
… We report here expression of HSP70 in tissues derived from GnRH agonist (GnRHa)-untreated and -treated women with adenomyosis and uterine myoma.Study designThis is a case-controlled biological study. …
NAID 120005553903

Lysophosphatidylserine analogues differentially activate three LysoPS receptors

Uwamizu Akiharu,Inoue Asuka,Suzuki Kensuke [他]
The journal of biochemistry 157(3), 151-160, 2015-03
NAID 40020395538

新規糖尿病治療薬の開発動向 (特集糖尿病治療薬update : 適正な血糖管理を目指して) -- (特論)

神山博史,寺内康夫
日本臨床 73(3), 517-522, 2015-03
NAID 40020367431

Related Pictures

★リンクテーブル★

リンク元	「アンタゴニスト」「アゴニスト」「agent」「セロトニン作動薬」「受容体刺激薬」
拡張検索	「excitatory amino acid agonist」「antagonist muscle」「irreversible antagonist」「metabolic antagonist」

「アンタゴニスト」

　　[★]

英: antagonist
同: 拮抗薬、遮断薬、類似体拮抗物質 analog inhibitor

アゴニスト	作用薬	agonist	内因性の化学情報伝達物質と同じ受容体に結合し、同じ生理作用を呈する
アンタゴニスト	拮抗薬	antagonist	内因性の化学情報伝達物質と同じ受容体に結合するが、生理作用を呈しない
	部分作用薬	partial agonist	拮抗薬のうち、弱いながら生理作用を呈する
	部分拮抗薬	partial antagonist	拮抗薬のうち、弱いながら生理作用を呈する

「アゴニスト」

　　[★]

英: agonist
同: 作用薬、作動薬
関

アゴニスト	作用薬	agonist	内因性の化学情報伝達物質と同じ受容体に結合し、同じ生理作用を呈する
アンタゴニスト	拮抗薬	antagonist	内因性の化学情報伝達物質と同じ受容体に結合するが、生理作用を呈しない
	部分作用薬	partial agonist	拮抗薬のうち、弱いながら生理作用を呈する
	部分拮抗薬	partial antagonist	拮抗薬のうち、弱いながら生理作用を呈する